One Decade In and Counting: How 503B Outsourcing Facilities Are Finding Their Place in the Industry.
Level 5 - mechanism / opinion, no new human data
Narrative commentary and opinion without empirical or experimental data (graded by non-clinical design analogy).
What was done
The article presents a narrative commentary examining the market role, regulatory integration, and industry trajectory of Section 503B compounding outsourcing facilities in the United States over the decade following the Drug Quality and Security Act of 2013.
What was found
The abstract reports that approximately 90 outsourcing facilities have registered with the US FDA since the 2013 legislation took effect. Practitioners, pharmacies, and clinics have increasingly integrated their services into standard business practices. No other quantitative metrics or statistical analyses are reported in the abstract.
Why it matters
It provides an industry-level overview of how the 503B regulatory framework has evolved to supply compounded drugs across the US healthcare system over its first ten years.
Limits
This is a narrative commentary and descriptive overview lacking empirical clinical data, systematic review methods, or quantitative outcome analyses.
Cited by
- supports Section 503B compounding pharmacies were created under federal legislation during the Obama administration.